Technologies related to Infectious diseases

Biological/Research Material for H1N1 Influenza Virus Vaccine Research
Ref: E-260-2009-0 | Updated: Sep 10, 2015
Biological/Research Material for HIV Vaccine Research
Ref: E-258-2009-0 | Updated: Sep 10, 2015
Neutralization of Hepatitis C Virus (HCV)
Ref: E-276-2007-1 | Updated: Oct 7, 2009
Bactericidal Peptides from Avian Leukocyte Ribonuclease A-2
Ref: E-281-2006-0 | Updated: Sep 18, 2009
Monoclonal Antibodies That React With the Capsule of Bacillus anthracis
Ref: E-125-2008-0 | Updated: Aug 31, 2009
Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses
Ref: E-078-2009-0 | Updated: Aug 31, 2012
Antigen Mixtures for Serological Detection of HHV-8 Infection
Ref: E-063-2009-0 | Updated: May 6, 2018
Recombinant Vaccines Based on Poxvirus Vectors
Ref: E-552-1982-2 | Updated: Aug 18, 2015
A Unique Infectious Hepatitis C Virus Clone, Strain HC-TN (genotype 1a)
Ref: E-249-2007-0 | Updated: Jul 14, 2009
qPCR Assay for Detection of JC Virus
Ref: E-152-2009-0 | Updated: Jun 3, 2010
A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry
Ref: E-005-2009-0 | Updated: Jun 16, 2010
Enhanced Immune Response Against Influenza Virus by Priming with a DNA-based Vaccine
Ref: E-341-2008-0 | Updated: Jun 8, 2009
Axenically-Produced Coxiella burnetii and Methods for Producing Axenic Coxiella burnetii
Ref: E-114-2009-0 | Updated: Jun 1, 2009
Therapeutic Methods Based on In Vivo Modulation of the Production of Interferon gamma
Ref: E-255-2000-0 | Updated: Nov 20, 2013
Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use
Ref: E-142-2008-0 | Updated: Jun 14, 2010
Sialostatin Mediation Controls Blood-feeding Success of the Tick Ixodes scapularis
Ref: E-289-2007-0 | Updated: Feb 2, 2009
Use of Mono-Amine Oxidase Inhibitors to Prevent Herpes Virus Infections and Reactivation from Latency
Ref: E-275-2008-0 | Updated: Oct 18, 2010
Anti-Plasmodium Compositions and Methods of Use
Ref: E-004-2004-2 | Updated: May 24, 2016
Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region
Ref: E-159-2007-3 | Updated: Feb 28, 2011
Live Attenuated Virus Vaccines for La Crosse Virus and Other Bunyaviridae
Ref: E-158-2007-3 | Updated: Jul 1, 2014
Generation of Wild-Type Dengue Viruses for Use in Rhesus Monkey Infection Studies
Ref: E-042-2008-0 | Updated: Sep 12, 2012
Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus
Ref: E-357-2001-1 | Updated: Sep 10, 2015
Development of Dengue Virus Type 3 Vaccine Candidates
Ref: E-139-2006-0 | Updated: May 9, 2016
Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses
Ref: E-120-2001-0 | Updated: Feb 28, 2011
Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4
Ref: E-089-2002-1 | Updated: May 6, 2016
Development of Antigenic Chimeric St. Louis Encephalitis Virus/Dengue Virus Type Four Recombinant Viruses (SLEV/DEN4) as Vaccine Candidates for the Prevention of Disease Caused by SLEV
Ref: E-240-2007-0 | Updated: Feb 28, 2011
Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines
Ref: E-268-2002-0 | Updated: Sep 1, 2008
Human Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus and Human Neutralizing Antibodies to Respiratory Syncytial Virus
Ref: E-032-1993-1 | Updated: Sep 1, 2008
Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus
Ref: E-001-1996-0 | Updated: Sep 1, 2008
A Novel Treatment for Malarial Infections
Ref: E-202-2008-0 | Updated: Apr 21, 2016
Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation
Ref: E-225-2000-0 | Updated: Sep 1, 2008
Human-Bovine Chimeric Respiratory Syncytial Virus (RSV) Vaccines
Ref: E-178-1999-0 | Updated: Sep 1, 2008
Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus
Ref: B-056-1994-1 | Updated: Feb 14, 2013
A Prophylactic and Therapeutic for Preventing and Treating Tularemia by Rapid Activation of Host Cells and Antigen Recognition
Ref: E-095-2008-0 | Updated: May 16, 2018
Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins
Ref: E-212-2003-0 | Updated: May 16, 2018
Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus)
Ref: E-283-2003-0 | Updated: May 16, 2018
Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome
Ref: E-214-2003-0 | Updated: May 16, 2018
Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)
Ref: E-198-2003-0 | Updated: May 16, 2018
Assay for Identification of Influenza-Neutralizing Antibodies
Ref: E-323-2007-0 | Updated: Apr 1, 2008
Codon Optimized Genes for Subunit Vaccines
Ref: E-326-2006-1 | Updated: Apr 1, 2008
Influenza Vaccines, Therapeutics, and Monoclonal Antibodies
Ref: E-116-2006-0 | Updated: Oct 21, 2009
Modulators of Nuclear Hormone Receptor Activity: Novel Compounds, Diverse Applications for Infectious Diseases, Including Anthrax (B. anthracis)
Ref: E-247-2002-1 | Updated: Jun 14, 2010
PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus
Ref: E-239-2007-3 | Updated: May 7, 2018
HIV Monoclonal Antibodies
Ref: E-109-2008-0 | Updated: May 18, 2018
The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection
Ref: E-055-2007-0 | Updated: Feb 28, 2014
Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers
Ref: E-208-2007-0 | Updated: Jun 14, 2010
Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag
Ref: E-241-2001-1 | Updated: Dec 1, 2007
Hepatitis C Virus Cell Culture System
Ref: E-324-2007-0 | Updated: Feb 15, 2013
Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
Ref: E-263-2005-0 | Updated: May 7, 2018
Method for Inducing T-Cell Proliferation
Ref: E-104-2004-1 | Updated: Sep 15, 2015
Probe Set Global Optimization
Ref: E-332-2005-0 | Updated: Aug 1, 2007
Methods for Prevention and Treatment of Polyomavirus Infection or Reactivation (E-179-2007)
Ref: E-179-2007-0 | Updated: Jun 14, 2010
Recombinant Baculoviruses Containing Inserts of the Major Structural Genes (vp1) of the Human Polyomaviruses JCV and BKV
Ref: E-216-2006-0 | Updated: Aug 1, 2007
Antiviral Compounds with Broad Neutralization Capabilities
Ref: E-013-2006-1 | Updated: Feb 17, 2021
A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes
Ref: E-248-2006-0 | Updated: Sep 22, 2015
Viral Entry or Replication Inhibitors
Ref: E-151-2006-0 | Updated: Jun 14, 2010
Peptide Mimotope Candidates for Otitis Media Vaccine
Ref: E-344-2002-0 | Updated: Jun 16, 2010
Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor)
Ref: E-258-2007-0 | Updated: Sep 19, 2017
CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection
Ref: E-090-1996-0 | Updated: Jun 1, 2007
Methods for Prevention and Treatment of Polyomavirus Infection or Reactivation
Ref: E-101-2007-0 | Updated: Jun 14, 2010
Increased Protein Expression Vector for Vaccine Applications
Ref: E-241-2001-0 | Updated: Jun 1, 2007
Enhanced, Targeted Delivery for DNA Vaccines
Ref: E-043-2006-0 | Updated: May 1, 2007
High Level Expression and Purification of Untagged and Histidine-tagged Human Immunodeficiency Virus Type-1 Reverse Transcriptase
Ref: E-141-2007-0 | Updated: Aug 24, 2015
Novel System for HIV-1 Vaccine Development
Ref: E-218-2004-0 | Updated: Mar 1, 2007
Method for Producing Significant Amounts of B19 Virus for Development of Killed or Attenuated Vaccines
Ref: E-188-2006-0 | Updated: Apr 21, 2016
Vaccine Production Strain for Acellular Pertussis Vaccine
Ref: E-159-1999-0 | Updated: Sep 16, 2015
Novel Acylthiol Compositions and Methods of Making and Using Them Against HIV
Ref: E-329-2000-0 | Updated: Mar 13, 2015
Molecules for Studying Cellular Immune Responses to Vaccines and Therapeutics
Ref: E-251-2006-0 | Updated: Aug 1, 2006
Monoclonal Antibody for Lyme Disease Diagnostic and Research
Ref: E-075-2006-0 | Updated: May 1, 2006
Identification of Candidate Ligands which Modulate Antigen Presenting Cells
Ref: E-055-1999-0 | Updated: May 1, 2006
Methods and Compositions for the Inhibition of SARS-CoV Replication Propagation and Transmission
Ref: E-253-2005-0 | Updated: Dec 1, 2005
Identification of a Fusion/Entry Receptor for Human Herpesvirus-8
Ref: E-051-2005-0 | Updated: Nov 1, 2005
Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines
Ref: E-092-2002-0 | Updated: Sep 1, 2005
Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development
Ref: E-337-2004-0 | Updated: May 24, 2016
Cell Culture System for Efficient Expression of Self-Replicating Norwalk Virus
Ref: E-043-2005-0 | Updated: May 8, 2018
VAC-BAC Shuttle Vector System for Generating Recombinant Poxviruses
Ref: E-355-2001-2 | Updated: Sep 16, 2015
Candidate DNA HIV Vaccine
Ref: E-267-2004-0 | Updated: Apr 1, 2005
Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria
Ref: E-176-2003-0 | Updated: Apr 1, 2005
MVA Expressing Modified HIV envelope, gag, and pol Genes
Ref: E-023-2003-0 | Updated: Apr 1, 2005
Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins
Ref: E-160-2002-0 | Updated: Mar 1, 2005
Anti-Plasmodium Compositions and Methods of Use
Ref: E-049-2004-0 | Updated: Feb 28, 2011
Protozoan Derived Antagonist of CCR5
Ref: E-272-2004-0 | Updated: Oct 1, 2004
Anti-Vaccinia Monoclonal Antibody
Ref: E-123-2004-0 | Updated: May 16, 2018
Inhibition of HIV Replication in Resting CD4+ Lymphocytes by Murr1
Ref: E-042-2004-0 | Updated: Jun 1, 2004
Mechanisms for Improving the Breadth of the Immune Response to Diverse Strains and Clades of HIV
Ref: E-335-2003-0 | Updated: Jun 1, 2004
SAP/SH2D1A Knockout Mice: A Model for X-linked Lymphoproliferative Disease
Ref: E-343-2003-0 | Updated: Jun 16, 2010
Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene
Ref: E-041-2004-0 | Updated: Sep 19, 2017
Streptococcus Lipoprotein Antigens
Ref: E-324-2003-0 | Updated: Jan 1, 2004
Inhibitors of Formation of Protease Resistant Prion Protein
Ref: E-189-1998-0 | Updated: May 7, 2018
HIV-Dependent Expression Vector
Ref: E-276-2003-0 | Updated: Nov 18, 2015
Factors That Bind Intestinal Toxins
Ref: E-223-2002-0 | Updated: Nov 1, 2003
Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection
Ref: E-130-2002-0 | Updated: Sep 22, 2015
HTLV-1 Cell Binding and Inhibition
Ref: E-240-2002-0 | Updated: May 1, 2003
Recombinant of Respiratory Syncytial Virus (RSV) Expressing Green and/or Red Fluorescent Protein
Ref: | Updated: Mar 1, 2003
4G10, a Monoclonal Antibody Against the Chemokine Receptor CXCR4, Raised Against a Synthetic Peptide of 38 Residues in Length Derived from the N-terminal Sequence of CXCR4
Ref: E-340-2002-0 | Updated: Feb 1, 2003
Assays for Assembly of Ebola Virus Pseudoparticles Relevant to Antiviral Therapy and Vaccines
Ref: E-090-2002-0 | Updated: Dec 1, 2002
Modified Defensins and Their Use
Ref: E-080-2002-0 | Updated: Nov 1, 2002
Immunization for Ebola Virus Infection
Ref: E-246-2001-0 | Updated: May 1, 2002
Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor to Enhance Immune Response and Inflammation
Ref: E-051-2002-0 | Updated: Apr 2, 2015
N-Formyl Peptide Receptor Mediation of Platelet Chemotaxis Toward Injured Cells and Activation of Immune Response
Ref: E-282-2001-0 | Updated: Feb 1, 2002


Subscribe to Technologies related to Infectious diseases